Inhibikase Therapeutics (IKT) Free Cash Flow Growth (1y) (2021 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 31.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 58.53% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -123.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -123.23% |
| Mar 31, 2026 | -192.93% |
| Dec 31, 2025 | -40.60% |
| Sep 30, 2025 | -117.02% |
| Jun 30, 2025 | -10.29% |
| Mar 31, 2025 | -6.46% |
| Dec 31, 2024 | -55.28% |
| Sep 30, 2024 | -18.90% |
| Jun 30, 2024 | -10.71% |
| Mar 31, 2024 | 35.25% |
| Dec 31, 2023 | 3.20% |
| Sep 30, 2023 | 28.04% |
| Jun 30, 2023 | -4.81% |
| Mar 31, 2023 | -51.80% |
| Dec 31, 2022 | 13.17% |
| Sep 30, 2022 | -182.35% |
| Jun 30, 2022 | -2.57% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | -332.72% |
| Sep 30, 2021 | -2,775.62% |